CYTO is a hot still relatively undiscovered prospect with no current analyst coverage, which should change in weeks. No FDA risk here, the stuff is approved and going to market and the story just keeps getting better. They are still out of favor due to their old Oncoscint product never making its marketing targets, but they shouldn't have that problem with QUAD the new drug and have Prostascint approved too. CYTO's my second biggest position after my 35 bagger INCY (ex-employee with cheap options to start with). It is also the biggest position in the VD Biotech Model:|
Do your own DD of course, nothing is a sure bet, but some are a lot surer than others!
Check out MATX and CMTR too. They'll be taking off Wed. on good news that is only just the beginning (IMHO of course).